Rolf M Mesters - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Rolf M Mesters

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

Cancers|June 11, 2020

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphomaUlrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.

Leukemia|June 12, 2019

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.

Pageof 7

Search research articles

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

Cancers|June 11, 2020

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphomaUlrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.

Leukemia|June 12, 2019

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.

Pageof 7